A novel camptothecin analog with enhanced antitumor activity
Garret Yount1, Yang Yang, Brian Wong
1California Pacific Medical Center Research Institute, San Francisco, CA 94107, USA.
Anticancer Research
|November 1, 2007
Summary
A novel camptothecin (CPT) derivative, CPT417, demonstrates reduced toxicity and superior antitumor activity compared to existing CPT analogs like topotecan. This stable CPT derivative shows promise for enhanced cancer treatment efficacy.
Area of Science:
- Oncology
- Pharmacology
- Medicinal Chemistry
Background:
- Camptothecin (CPT) derivatives are potent anticancer agents but suffer from severe toxicity and structural instability.
- Current CPT analogs have limitations impacting their clinical utility.
- Development of stable and less toxic CPT derivatives is crucial for improved cancer therapy.
Purpose of the Study:
- To evaluate the biological activity and therapeutic potential of a novel, stable camptothecin derivative, CPT417.
- To compare the efficacy and toxicity of CPT417 against established CPT analogs, specifically topotecan and irinotecan.
- To assess the anticancer effects of CPT417 in preclinical models of glioblastoma, colon cancer, and mammary adenocarcinoma.
Main Methods:
- In vitro cytotoxicity assays including vital dye exclusion, timelapse microscopy, and colony formation assays were performed on glioblastoma and colon cancer cell lines.
- In vivo efficacy was evaluated in mice bearing subcutaneous mammary adenocarcinoma tumors.
- Comparative analysis with topotecan and irinotecan was conducted for both in vitro and in vivo studies.
Main Results:
- CPT417 exhibited comparable inhibition of glioblastoma cell growth to topotecan.
- CPT417 demonstrated superior inhibition of colon cancer cell clonogenicity compared to irinotecan.
- CPT417 significantly enhanced mammary tumor growth inhibition versus topotecan, irrespective of administration route (intraperitoneal or oral).
Conclusions:
- CPT417 displays significantly reduced toxicity compared to topotecan.
- CPT417 possesses enhanced antitumor activity, positioning it as a promising candidate for further clinical development.
- The stable structure of CPT417 contributes to its improved therapeutic profile.
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...